How Prostac™ Works

Early, precise prostate cancer detection

NucleoBio's scientists are pioneers in molecular biology research and the in-depth study of DNA. It was this research that led to the discovery of the multiplexing of PVT1 exons 4A, 4B, and 9, and the development of our Prostac™ diagnostic test.

Specifically, Prostac™ is a Nucleic acid amplification test (qRT-PCR) that uses PVT1 primers to quantify the concentration (in copies/µL) of the multiplexing PVT1 exons 4A, 4B and 9 found in the long, non-coded region of the mRNA in the PVT1 gene.

Leveraging generative Artificial Intelligence, NucleoBio uses a computational algorithm incorporating copies / uL of PVT1 exons 4A, 4B, and 9 to compute a Prostac™ Score. With this score, Prostac™ can distinguish between indolent and aggressive prostate cancer and identify the risk group (i.e. stratification).

The accuracy, sensitivity, specificity and predictive values of Prostac™ have been peer reviewed. In the future, generative AI will aid faster and more accurate computation, and subsequent interpretation.

We have developed a proprietary, molecular-based platform that will enable the early detection of additional cancers with same unparalleled precision that can empower physicians to prescribe data-driven and personalized life-saving interventions.